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Abstract
According to the World Anti-Doping Agency (WADA) regulations, cannabinoids use
is prohibited in competition except for cannabidiol (CBD) use. For an adverse
analytical finding (AAF) in doping control, cannabinoid misuse is based on identifica-
tion of the pharmacologically inactive metabolite 11-nor-delta-9-carboxy-tetrahydro-
cannabinol-9-carboxylic acid (carboxy-THC) in urine at a concentration greater than
180 ng/ml. All other (minor) cannabinoids are reported as AAF when identified,
except for CBD that has been explicitly excluded from the class of cannabinoids on
WADA's Prohibited List since 2018. However, due to the fact that CBD isolated from
cannabis plants may contain additional minor cannabinoids, the permissible use of
CBD can lead to unintentional violations of antidoping regulations. An assay for the
detection of 16 cannabinoids in human urine was established. The sample prepara-
tion consisted of enzymatic hydrolysis of glucuronide conjugates, liquid–liquid extrac-
tion, trimethylsilylation, and analysis by gas chromatography/tandem mass
spectrometry (GC–MS/MS). Spot urine samples from CBD users, as well as speci-
mens obtained from CBD administration studies conducted with 15 commercially
available CBD products, were analyzed, and assay characteristics such as selectivity,
reproducibility of detection at the minimum required performance level, limit of
detection, and limit of identification were determined. An ethical committee
approved controlled single dose commercially available CBD products administration
study was conducted to identify 16 cannabinoids in urine samples collected after inges-
tion or application of the CBD products as well as their presence in spot urine samples
of habitual CBD users. Variable patterns of cannabinoids or their metabolites were
observed in the urine samples, especially when full spectrum CBD products were con-
sumed. The presence of minor cannabinoids or their metabolites in an athlete's in-
competition urine sample represents a substantial risk of an antidoping rule violation.
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1 | INTRODUCTION
The use of cannabinoids is prohibited in sports competition.1
11-Nor-delta-9-carboxy-tetrahydrocannabinol-9-carboxylic acid
(carboxy-THC) is presently the main target analyte for the detection
of cannabis misuse in doping control urine samples,2 with a urinary
threshold of 150 ng/ml.3 According to the World Anti-Doping Agency
(WADA) Technical Document TD2019DL, a sample shall be reported
as an adverse analytical finding (AAF) when the value exceeds the
decision limit of 180 ng/ml.3 For other (minor) cannabinoids, no
thresholds exist. Consequently, when identified in in-competition
doping control urine samples according to WADA regulations,4 an
AAF is reported by the antidoping laboratory.
Cannabidiol (CBD) does not produce the euphoria and tachycar-
dia of Δ9-tetrahydro-cannabinol5 and was excluded from WADA's
Prohibited List1 on January 1, 2018. Yet it was clarified by WADA and
others6,7 that CBD products, manufactured from cannabis plant
extracts, may also containTHC,8 or varying concentrations of (banned)
cannabinoids9 that could lead to an AAF when an athlete is subjected
to routine doping controls.
Globally, there is a substantial increase in the use of over-the-
counter CBD products, despite the lack of scientific data for the
drug's efficacy for different indications.10–12 One pharmaceutical CBD
product (Epidiolex®) is currently approved in Europe for the therapy
of a serious form of epilepsy in children (Dravet syndrome).13 How-
ever, CBD products are frequently sold as nutritional supplements,
novel foods, or cosmetics and can be purchased in pharmacies,
organic shops, drugstores, supermarkets, and via the Internet, and a
growing receptivity amongst elite athletes is conceivable.14–16
Multiple publications are available for the analysis of cannabis
intake,17–19 with analytical methods being largely based on gas
chromatography–mass spectrometry (GC–MS)20,21 and/or liquid
chromatography-mass spectrometry (LC–MS).18,19,22 In order to
clarify whether the permissible use of different CBD products can
lead to unintentional violations of the antidoping regulations, similar
analytical strategies were pursued in this study to assess the risks
associated with CBD consumption by athletes during routine doping
controls. Therefore, a GC–MS-based detection method for various
cannabinoids in human urine was developed and validated, and 15 -
different commercially available CBD products (oils, pastes, capsules,
crystals) were purchased (Table 1). Elimination studies were
performed in healthy volunteers who consumed the CBD products
following the manufacturers' dosage recommendations and provided
postadministration urine samples. The excretion study was performed
with approval (number 060/2020) of the ethical committee of the
German Sport University Cologne (Germany) and written informed
consent was obtained from all participants. Urine samples were ana-
lyzed for the presence of doping-relevant cannabinoids by means of
GC–MS. In addition, spot urine samples obtained from habitual CBD
users were tested for cannabinoids using the established approach.
These proof-of-concept investigations were performed to determine
the risk of an inadvertent AAF resulting from the intake or application
of permitted CBD products and to initiate a discussion about future
reporting levels for minor cannabinoids in sports drug testing.
2 | EXPERIMENTAL
2.1 | Chemicals and reagents
All solvents and reagents were of analytical grade purity.
Tert-Butyl methyl ether (TBME) was purchased from AppliChem
TABLE 1 CBD products for administration studies
Product Formulation Application route Manufacturer information CBD dose (mg)
1 Oil Oral 63% Hemp seed oil, 37% hemp extract 12
2 Powder Oral 99.6% CBD crystals 50
3 Oil Oral 2400 mg CBD/10 ml hemp seed oil—Full spectrum (CBG, CBN) 44
4 Oil Oral 2000 mg CBD/10 ml hemp oil, hemp extract, isolate—full spectrum 36
5 Capsule Oral Hemp oil/300 mg hemp extract per capsule Unknown
6 Oil Oral 1000 mg CBD/10 ml hemp seed oil 50
7 Oil Oral 3% CBD in hemp oil—full spectrum 50
8 Oil Oral 1000 mg CBD/10 ml hemp seed oil—decarboxylated 50
9 Oil Oral 500 mg CBD/10 ml hemp seed oil 25
10 Oil Oral 500 mg CBD/10 ml hemp oil—full spectrum (CBN, CBV, CBG, CBC) 25
11 Oil Oral 1000 mg CBD/10 ml hemp oil—full spectrum (CBN, CBV, CBG, CBC) 50
12 Aq sol Oral 250 mg CBD/10 ml water (aq sol: Aqueous solution) 11.25
13 Capsule Oral 25 mg CBD/hemp oil per capsule 50
14 Oil Oral 1000 mg CBD/10 ml hemp oil—full spectrum 50
15 Gel Transdermal 10% CBD 20
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(Darmstadt, Germany) and distilled before use. β-Glucuronidase
from Escherichia coli was supplied by Roche Diagnostics
GmbH (Mannheim, Germany) and Red Abalone β-glucuronidase
from Ango Science (Santiago, Chile). N-Methyl-N-trimethylsilyl-
trifluoroetamide (MSTFA) was obtained from Machery &
Nagel (Düren, Germany). All solutions and buffers were prepared
using deionized water (Water Lab System, Millipore, Eschborn,
Germany).
The following certified standards were purchased from LGC
Promochem (Wesel, Germany): Δ8-tetrahydrocannabinol (Δ8-THC),
Δ9-tetrahydrocannabinol (THC), 11-OH-Δ9-tetrahydro-cannabinol
(11-OH-THC), CBD, cannabigerol (CBG), cannabinol (CBN),
cannabidivarin (CBDV), cannabichromene (CBC),
Δ9-tetrahydrocannabidivarin (THCV), Δ9-tetrahydrocannabinol acid
(THCA), cannabidiol acid (CBDA), cannabigerol acid (CBGA),
cannabinol acid (CBNA), cannabidivarinic acid (CBDVA),
cannabichromene acid (CBCA), Δ9-tetrahydrocannabidivarinic acid
(THCVA), d3-Δ9-tetrahydrocannabinol (d3-THC), d3-11-OH-Δ9-
tetrahydrocannabinol (d3-11-OH-THC), d3-cannabidiol (d3-CBD),
d3-cannabinol (d3-CBN). 17α-Methyltestosterone was obtained from
Serva, Heidelberg, Germany.
2.2 | CBD products
A total of 15 CBD products (14 products for oral administration, one
gel for transdermal application) were obtained from Internet shops,
pharmacies and CBD manufacturers (Table 1).
2.3 | Sample preparation
Cannabinoids are excreted unconjugated and conjugated (primarily
as glucuronidated phase-II metabolites).18,20,23,24 In order to detect
both, free and conjugated urinary cannabinoid metabolites, as well
as to increase the analytical sensitivity, a hydrolysis step during the
sample preparation is frequently recommended and employed.
Hence, 2 ml urine was fortified with 50 ng of the internal stan-
dards d3-THC, d3-11-OH-THC, d3-CBD, d3-CBN, and 17α-
methyltestosterone. The samples were buffered to pH 7.0 with
0.75 ml 0.8 M phosphate buffer (Na2HPO4:NaH2PO4, 1:2, w:w).
Twenty-five microliters β-glucuronidase from E. coli were added.
The mixture was incubated at 50C for 1 h. After cooling to
ambient temperature, the pH was adjusted to 9.6 by the addition
of 0.5 ml aqueous potassium carbonate and potassium hydrogen
carbonate (20%, 1:1, w:w). Five milliliter TBME were added, and
the mixture was shaken for 5 min and subsequently centrifuged at
598 g for 5 min. The organic layer was transferred to a fresh glass
tube, evaporated to dryness at 50C using a rotary evaporator
under reduced pressure, and the dry residue derivatized
with 100 μl MSTFA/NH4I/ethanethiol 1000:2:3 (v:w:v) for
20 min at 60C.
An alternative hydrolysis protocol in accordance with earlier pub-
lished approaches was employed to verify the analytical method for
the detection of cannabinoids. Here, 40 μl β-glucuronidase from Red
Abalone (5200 units) were utilized, and the hydrolysis was performed
at pH 5 (adjusted using sodium acetate buffer) applying an incubation
period of 4 h at 37C.24 The comparison of conjugate hydrolysis effi-
cacy was done using five urine specimens obtained from administra-
tion studies performed with full spectrum CBD products. The samples
were prepared twice in triplicate and hydrolyzed with E. coli or Red
Abalone, respectively.
2.4 | Gas chromatography/tandem mass
spectrometry
All analyses were performed using aThermo ScientificTSQ 8000 tandem
mass spectrometer coupled to a Thermo Scientific Trace 1310 gas chro-
matograph (Thermo Fisher Scientific, Dreieich, Germany). A J&W Scien-
tific Ultra I (OV-1) column (length 17 m, I.D. 0.2 mm, film thickness
0.11 μm) was employed, and helium was used as carrier gas at a head
pressure of 16 psi.
An 1.8 μl aliquot of the sample was injected into the GC system,
which was operated in split (1:10) mode. The GC temperature was
ramped as follows: initial temperature 185C, program rate 3C min−1
to 234C, program rate 40C min−1 to 310C, constant temperature
at 310C for 2 min. The injection port and transfer line were heated
to 300C.
The trimethylsilylated analytes were measured using selected
reaction monitoring (SRM) with electron ionization (EI), and the
corresponding diagnostic ion transitions for each compound are
presented inTable 2.
2.5 | Urine SG
Cannabinoid concentrations were adjusted to a urine specific
gravity (SG) of 1.020 based on the following equation:
Conccorr = Concmeasured * (1.020 − 1)/(SG-1).
The SG measurements were performed on a PAAR Refractometer
Abbemat 350 (Osterfildern, Germany) with automatic sampling.
2.6 | Excretion study urine samples
Following written consent, study participants (three males, five
females, 42–66 years old) were administered one CBD product each
per trial, according to the recommended dosage of the manufacturer
(Table 1), and urine samples were collected before and 8, 16, and 32 h
after product administration. For five CBD products (numbers 2, 3,
7, 11, 14, Table 1), two volunteers were available for administration
studies. The urine specimens were stored frozen until analysis for up
to 8 weeks.
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TABLE 2 Summary of compound properties
Compound Abbreviation RT (min) IT (m/z) CE (V) LOD (ng/ml) LOI (ng/ml)
Cannabidivarin CBDV 4.16 362.3/273.2 7 0.18 0.18
362.3/319.3 7
362.3/231.2 17
Δ9-Tetrahydrocannabivarin THCV 4.93 358.3/315.3 9 0.35 0.18
358.3/275.2 19
358.3/261.2 23
d3-Cannabidiol d3-CBD 6.14 393.3/304.3 7
Cannabidiol CBD 6.21 390.3/301.3 7 0.15 0.80
390.3/319.3 7
390.3/244.2 11
Cannabichromene CBC 7.11 303.3/246.2 24 0.10 0.10
303.3/174.1 35
303.3/231.2 27
Δ8-Tetrahydrocannabinol Δ8-THC 7.21 303.3/246.2 24 0.45 0.30
303.3/174.1 35
303.3/231.2 27
d3-Δ9-Tetrahydrocannabinol d3-Δ9-THC 7.45 374.3/292.2 9
Δ9-Tetrahydrocannabinol THC 7.50 371.3/289.2 9 0.18 0.40
371.3/305.3 7
371.3/265.2 7
Cannabidivarinic acid CBDVA 8.18 463.3/373.3 9 0.45 0.80
463.3/147.1 33
463.3/133.1 31
d3-Cannabinol d3-CBN 8.79 370.3/310.3 25




Cannabigerol CBG 8.95 337.3/321.3 9 0.95 0.46
337.3/263.2 9
337.3/249.2 13
Δ9-Tetrahydrocannabivarinic acid THCVA 10.09 459.3/147.1 33 0.15 0.60
459.3/337.3 9
459.3/379.3 9








d3–11-Hydroxy-tetrahydrocannabinol d3-11-OH-THC 12.39 374.3/292.2 9
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2.7 | Spot urine samples of CBD users
In addition to the above-mentioned controlled administration studies,
also spot urine samples of seven customary CBD users were collected.
The volunteers provided additional information concerning the formu-
lation, dosage, and frequency of the product usage. The urine speci-
mens were stored frozen until analysis within 8 weeks. The collection
of spot urine samples was performed in agreement with the ethical
committee of the German Sport University Cologne (Germany).
2.8 | Determination of cannabinoids in human urine
The identification of the cannabinoids was performed by comparison
with adequate reference standards using a minimum of three
precursor-product ion transitions, meeting the requirements of the
WADA Technical Document TD2015IDCR.4
The estimation of the analytes' concentration was performed by
means of calibration curves (working range 1–11 ng/ml), utilizing the
peak area ratios of the quantifier ion transitions of analyte and inter-
nal standard. For substances with concentrations outside the calibra-
tion curve, the urine volume was adjusted.
3 | ASSAY VALIDATION
The assay validation was performed according to the requirements of
the WADA ISL.25
3.1 | Selectivity
Selectivity is the ability to differentiate the analyte of interest from
endogenous matrix interferences or from other substances present in
the sample. Ten different blank urine specimens with known origin
were prepared and analyzed as described above in order to probe for
interfering peaks in the selected ion transitions at the expected reten-
tion time. Additionally, it was shown that the positive quality control
sample produced the expected signal at the correct retention time for
each target analyte.
3.2 | Reproducibility of detection at the MRPL
Ten different blank urine specimens with known origin, spiked with
1 ng/ml of each target analyte, were prepared and analyzed to dem-
onstrate the reproducibility of detection at the minimum required per-
formance level (MRPL).
3.3 | Limit of detection
Six different representative urine samples, fortified at five
different percentage concentrations of the MRPL (5% = 0.05 ng/ml,
10% = 0.1 ng/ml, 20% = 0.2 ng/ml, 50% = 0.5 ng/ml,
100% = 1.0 ng/ml), were prepared and analyzed. The estimation of
the limit of detection (LOD) was performed by using a
detection response curve. The LOD is estimated as the
TABLE 2 (Continued)
Compound Abbreviation RT (min) IT (m/z) CE (V) LOD (ng/ml) LOI (ng/ml)












Methyltestosterone MT 14.94 446.3/301.3 20
301.3/169.1 15
Carboxy-THC THC-COOH 15.20 371.3/289.2 18
371.3/305.3 12
371.3/265.2 15
Note: For each compound examined, the observed retention time (RT), ion transitions (IT), and collision energy (CE) are presented. For target analytes
(internal standards excluded), limit of detection (LOD) and limit of identification (LOI) are also shown.
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concentration at which the response curve shows a 95% analyte
detection rate.
3.4 | Limit of identification
The limit of identification (LOI) is the lowest concentration of an
analyte, which meets the WADA TD IDCR4 criteria in 95% of
representative samples.
Six different representative urine samples, fortified at five
different percentage concentrations of the MRPL (5% = 0.05 ng/ml,
10% = 0.1 ng/ml, 20% = 0.2 ng/ml, 50% = 0.5 ng/ml,
100% = 1.0 ng/ml), were prepared and analyzed. The estimation of
the LOI was performed by using a detection response curve. The LOI
is estimated as the concentration at which the response curve shows
a 95% analyte identification rate.
4 | RESULTS AND DISCUSSION
The temporal indication of cannabis use is important in clinical evalua-
tions, in workplace drug testing, in crash and incident investigations,
in verifying or falsifying the accuracy of court testimonies, and for
routine doping controls. Here, Δ9-tetrahydrocannabinol (THC),
11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (carboxy-
THC) are the most frequent analytes for the situational assessment.
Additional cannabinoids, for example, CBD, CBN, CBG, THCV, and
THCVA were suggested for inclusion into such evaluations in order to
improve clinical and forensic result interpretations in blood, plasma,
and oral fluid.18,19,26 The detection of these analytes and other minor
cannabinoids as well as their urinary metabolites in in-competition
doping control urine samples would constitute an AAF. The herein
presented pilot study focused on seven intact minor cannabinoids
(i.e., CBG, CBN, CBC, CBDV, CBGA, THCA, and CBDA) without
corresponding predicted or established metabolic products. Targeting
urinary phase-I and/or phase-II metabolites might further extend the
detection windows for these minor cannabinoids, and follow-up
investigations would be warranted if prolonged retrospectivity is
desired, considering the fact that cannabinoids are currently banned
in-competition only.
4.1 | Assay validation
In order to assess the developed assay's analytical suitability, the
parameters selectivity, reproducibility of detection at the MRPL, LOD,
and LOI were determined according to the requirements of the
WADA ISL.25 Regarding selectivity, the investigation of 10 different
blank urine samples generated no interfering signals at the expected
retention times for the analytes. The detection of all cannabinoids
was possible at the 1 ng/ml MRPL. LOD and LOI were determined by
a detection response curve with five concentrations (Table 2). For
several substances (CBCA, CBG, THCV, Δ8-THC), the determined LOI
was lower than the corresponding LOD. This is attributed to the use
of a higher urine volume in the confirmation procedure. Figure 1
shows the extracted ion chromatograms of the investigated cannabi-
noids and internal standards.
The use of β-glucuronidase from Red Abalone as discussed in
CBD-dedicated analytical approaches24 resulted in an increase in uri-
nary CBD (1.2-fold–twofold) and CBDV (twofold–threefold) concen-
trations compared to hydrolysis with E. coli, suggesting a more
efficient hydrolysis of glucuronic acid conjugates. However, an
unsatisfactory deconjugation of relevant steroid profile markers
(androsterone, etiocholanolone, 5α-androstane-3α,17β-diol, 5β-
androstane-3α,17β-diol, testosterone, and epitestosterone) was
observed and, in the light of the fact that the use of β-glucuronidase
from E. coli is obligatory in sports drug testing initial testing proce-
dures for steroid profile-related analyses,27 it was decided to use
β-glucuronidase from Red Abalone in the confirmatory analysis
targeting cannabinoid-related analytes.
The fact that the precursor cannabinoid acids can generate their
decarboxylated counterparts under the influence of heat and light and
by means of spontaneous decarboxylation28 was taken into consider-
ation, especially since the decarboxylation of cannabinoid acids can
occur in the hot injector port of the GC or during the manufacturing
process of CBD products.29 As decarboxylation rates for the cannabi-
noid acids as determined in our study are 0.2% and 8.8%, the degrada-
tion was considered negligible.
4.2 | Excretion study urine samples
In Europe, CBD is primarily obtained from hemp containing a maxi-
mum of 0.2% THC, with the declaration on most products of “THC
free.” Nevertheless, a recent study of 67 food products on the
German market (mostly CBD oils) showed detectable THC in 25% of
the tested products,29,30 and the analysis of CBD oils in the Nether-
lands further corroborated this finding.31 The manufacturers of the
products administered in this study evidently employed low-THC can-
nabis material for their CBD products as no significant signals for THC
andrelatedmetabolitesweredetectedin the investigatedurinesamples.
Urine samples collected 8, 16, and 32 h after CBD administra-
tion according to the manufacturer's recommended dose (Table 1)
were analyzed for cannabinoids. In all urine samples collected 8 h
after administration, CBD was detectable in concentrations higher
than 5 ng/ml (Table 3). Despite similar amounts of CBD in the dif-
ferent products, urine concentrations were highly variable; for
example, 50 mg CBD in products 2, 6, 7, 8, 11, 13, and 14 led to
28–746 ng/ml CBD in urine. Administration of 44 mg CBD in prod-
uct 3 yielded maximum urinary CBD concentrations of 4485 ng/ml,
and 36 mg CBD via product 4 resulted in 1424 ng/ml urinary CBD
8 h after application. Of note, both products were declared as full
spectrum products. These results may be attributed to an incorrect
CBD content declaration (which was not confirmed prior to the
administration study) or to individual metabolism differences in the
volunteers.
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Intake of full spectrum cannabinoid CBD extracts and products
without specific CBD concentration declarations resulted in the
detection of various prohibited cannabinoids (Table 3) in the study
participants' urine over more than 30 h. This suggests a considerable
risk of antidoping rule violations for athletes (Table 3). The most abun-
dant urinary cannabinoid besides CBD was CBG reaching urine con-
centrations up to 800 ng/ml, followed by CBDV (maximum urinary
concentration ca. 95 ng/ml), CBN (maximum urinary concentration
ca. 4.6 ng/ml), and CBC (maximum urinary concentration
ca. 4.5 ng/ml). A full spectrum hemp seed oil (product 7) yielded
positive CBGA, THCA, and CBDA (Table 3) urine concentrations,
while none of the cannabinoid acids CBDVA, CBCA, CBNA, THCVA,
THCA nor THCV, Δ8-THC, THC or 11-OH-THC were detected in the
elimination study urine samples. Alarming however is that in 8 of
15 individuals (53%) the 8 h urine samples contained CBG, and in
12 of 15 individuals (80%) CBDV was detected, all of which would
constitute an AAF if the sample was collected from an athlete in-
competition. In three instances, CGB, CBC, and CBDV were identified
even 32 h postadministration (Table 3). The administration of five
selected products (product numbers: 2, 3, 7, 11, 14) to an additional
F IGURE 1 Extracted ion chromatograms of cannabinoids and respective internal standards (10 ng/ml) [Colour figure can be viewed at
wileyonlinelibrary.com]
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set of volunteers resulted in urinary cannabinoid patterns and detec-
tion windows similar to those observed in the initial administration
study (Table 3).
4.3 | Spot urine samples from CBD users
The analyzed spot urine samples showed high variability in cannabi-
noids presence (Table 4). Transdermal CBD gel application only
achieved 5 ng/ml urinary CBD concentration, with no other cannabi-
noids detected.
Subjects taking CBD products for chronic pain therapy or to cure
sleep disorders had CBD as well as CBG, CBN, CBC, CBDV, and
CBDVA in their urine with maximum concentrations of 154 ng/ml for
CBG and 47 ng/ml for CBDV (Table 4). A typical example is shown in
Figure 2. These data contribute to the substantial risk of an antidoping
rule violation for athletes when using CBD products.
5 | CONCLUSION
The use of permitted CBD products can lead to findings of prohibited
cannabinoids in urine including e.g. CBG, CBN, CBC, and CBDV.
While the herein presented pilot study focused merely on seven
minor cannabinoids (i.e., CBG, CBN, CBC, CBDV, CBGA, THCA, and
CBDA) besides CBD and the threshold substance THC-COOH, the
risk of AAFs might be further aggravated by future consideration and
potential inclusion of minor cannabinoid urinary metabolites into dop-
ing control analytical assays. Here, the unequivocal coherence
between minor cannabinoid administration and corresponding urinary
metabolite detection will require further investigations, and relevant
reference material will be needed. In the light of the obtained data,
comprehensive information and thorough education of athletes con-
cerning the risks associated with the consumption of CBD products is
of utmost importance in order to avoid the risk of an unintentional
antidoping rule violation through the permitted use of CBD


















1 CBD gel Transdermal 10 mg 5.2
2 CBD oil 10% Oral 3 drops 85 16
3 CBD oil 10% Oral 3 × 5 drops 772 16 1.0 1.8 32 2.6
4 CBD oil 5% Oral 3 × 4 drops 116 3.0
5 CBD oil 10% Oral 10 drops 863 154 8.1 4.1 47
6 CBD oil 5% Oral 10 drops 511 112 4.9 3.5 20
7 CBD oil 10% Oral 10 drops 404 5.9
F IGURE 2 (a) Cannabinoids in an authentic urine specimen of a cannabidiol (CBD) user (no 6). Extracted ion-chromatograms of CBD,
cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), cannabidivarin (CBDV) and internal standard d3-CBD are shown.
(b) Corresponding blank urine sample [Colour figure can be viewed at wileyonlinelibrary.com]
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products6,8 and, possibly, revisiting reporting levels for cannabinoids
in the antidoping context are warranted.
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